Conduit Pharmaceuticals Inc..
CDT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Conduit Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies that address unmet medical needs. The company's pipeline includes treatments for autoimmune diseases, inflammatory conditions, and other serious illnesses. Conduit Pharmaceuticals aims to ...Show More
Better Health for All
10
Conduit Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune disorders and idiopathic male infertility, indicating a potential positive impact on health
1
,
2
. The company is using AI to expedite drug development, streamline drug repurposing, and enhance clinical trial monitoring
3
. Conduit retains 100% ownership of intellectual property for human applications
4
. The company's investor relations website aims to adhere to accessibility guidelines
5
. However, there is a lack of specific quantitative data on health impact, pricing, accessibility, or vulnerable reach
6
. Given the early stage of the company and the lack of concrete data, a score of +10 is appropriate, reflecting the potential for positive health impact with ongoing development.
7
Fair Money & Economic Opportunity
0
No evidence available to assess Conduit Pharmaceuticals Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data points were found across the provided articles for any of the KPIs related to Fair Pay & Worker Respect. Information regarding living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage is explicitly stated as unavailable or missing in the articles.
1
While some articles mention employee reviews and ratings (e.g., overall rating of 2.7 out of 5 stars, 58% employee recommendation), these are not direct measures of the specific quantitative metrics required by the rubric, such as a formal employee engagement index on a 100-point scale or a calculated turnover rate.
2
Executive compensation data is provided, but median employee compensation is not, preventing the calculation of a CEO median pay ratio.
3
Nasdaq compliance issues mentioned are not labor law violations.
4
Fair Trade & Ethical Sourcing
0
No specific, concrete data points related to fair trade or ethical sourcing, such as fair-trade certification share, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend, were found in the provided articles.
1
The articles primarily focus on business models, leadership, or general legal compliance, and explicitly state the absence of relevant quantitative data for these metrics.
2
Honest & Fair Business
-30
Conduit Pharmaceuticals Inc. had one financial restatement for the first two quarters of 2024 due to a misclassification of deferred commission payable.
1
Currently, 50% of the company's six-member board are independent directors.
2
A new director, Simon Fry, was appointed to the Audit and Compensation committees, with no material conflicts of interest reported for him.
3
Kind to Animals
0
No evidence available to assess Conduit Pharmaceuticals Inc. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess Conduit Pharmaceuticals Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Conduit Pharmaceuticals Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points relevant to the 'Respect for Cultures & Communities' value or its associated KPIs were found in the provided articles. Both articles explicitly state that they do not contain metrics related to community engagement, cultural sensitivity, social responsibility initiatives, partnerships, revenue reinvestment, cultural impact assessments, employment demographics, or grievance mechanisms.
1
Safe & Smart Tech
0
No specific, concrete evidence was found in the provided articles to assess Conduit Pharmaceuticals Inc. against any of the 'Safe & Smart Tech' KPIs. Information regarding data breaches, cybersecurity investment, and regulatory filings in Articles and pertained to 'Conduent', a different entity, and was therefore not considered relevant to Conduit Pharmaceuticals Inc.
1
Articles and mention Conduit Pharmaceuticals Inc. but only state that they leverage AI or are subject to regulations, without providing measurable facts about their practices, performance, or specific policies related to any KPI.
2
Zero Waste & Sustainable Products
0
No specific, concrete data points or initiatives related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found for Conduit Pharmaceuticals Inc. (CDT.US) in the provided articles.
1
One article explicitly states that sustainability data is currently not available for CDT.US.
2